An individual product theme focused on expanding the indications for JACE, an autologous cultured epidermis product, beyond severe burns to epidermolysis bullosa and giant congenital melanocytic nevi, pursuing regulatory applications, and increasing orders through evaluation of treatment outcomes and promotional initiatives.